Clinical trials: Carcinomas
Carcinoma, Non-Small-Cell Lung
Erlotinib and Sequential Positron Emission Tomography (PET) in Advanced Non Small Cell Lung Cancer (NSCLC)
This is a Phase-II Study to evaluate the accuracy of Fluorodeoxyglucose-/Fluorothymidine-Positron Emission Tomography (FDG-/FLT-PET) analyses for early prediction of non-progression in patients with non-small-cell lung cancer…
- Trial name
- ERLOPET (NCT00568841)
- Testing
- erlotinib, FDG-/FLT-PET
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Lung Cancer Group Cologne
Locally Advanced Nasopharyngeal Carcinoma
GP Combined With Nimotuzumab and Sintilimab as Induction Therapy for Nasopharyngeal Carcinoma
The goal of this clinical trial is to learn if the regimen of gemcitabine, cisplatin combined with nimotuzumab and sintilimab works to treat locally advanced nasopharyngeal carcinoma before chemoradiotherapy.
- Trial name
- NCT06490341
- Testing
- GP Regimen, Nimotuzumab, Sintilimab
- Volunteers
- 20 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Liver Neoplasms, Primary Liver Cancer
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
The goal of this observational study is to collect information on the use of the HistoSonics Edison System for the treatment of liver tumors.
- Conditions
- Liver Neoplasms, Primary Liver Cancer, Secondary Liver Cancer, Tumor Liver
- Trial name
- NCT06486454
- Testing
- HistoSonics Edison System
- Where
- 33 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- HistoSonics, Inc.
Squamous Cell Carcinoma of the Anal Canal
Tumor Recurrence After Abdominal-perineal Amputation in Squamous Cell Carcinoma of the Anus
Squamous cell carcinoma of the anal canal is a rare cancer with an increasing incidence. It represents 2.5% of digestive cancers and occurs more frequently in immunocompromised persons, in particular HIV positive.
- Trial name
- RTA (NCT05201105)
- Where
- France
- Volunteers
- 43 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Cholangiocarcinomas
PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine)
The purpose of this study is to determine the efficacy of panitumumab plus cisplatin/gemcitabine (CisGem) combination chemotherapy in KRAS wild-type biliary tract cancer patients without systemic pre-treatment, compared to the…
- Trial name
- PiCCA (NCT01320254)
- Testing
- Cisplatin, Gemcitabine, Panitumumab, Cisplatin, Gemcitabine
- Where
- 16 sites in Germany
- Volunteers
- 93 people
- Sponsor
- Hannover Medical School
Clinical Stage IV Gastric Cancer AJCC v8, Gastric Adenocarcinoma
Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis
This phase Ib trial test effects of aldesleukin in combination with nivolumab and standard chemotherapy in treating patients with gastric cancer that has spread to the tissue lining of the abdomen (peritoneal metastasis).
- Conditions
- Clinical Stage IV Gastric Cancer AJCC v8, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Carcinoma
- Trial name
- NCT05802056
- Testing
- Aldesleukin, Biopsy Procedure, Biospecimen Collection
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mayo Clinic
Hepatocellular Carcinoma, Liver Carcinoma
the Effect of Nutrition-optimized Prehabilitation on Perioperative Intervention in Primary Liver Carcinoma
This study aimed to evaluate whether nutritional optimization-led triple prehabilitation could improve perioperative nutritional status, promote postoperative recovery, and reduce postoperative complications in patients with…
- Conditions
- Hepatocellular Carcinoma, Liver Carcinoma, Hepatobiliary Cancers, Primary Liver Cancer
- Trial name
- NCT06549829
- Testing
- Nutritional optimization-led triple prehabilitation Intervention, Conventional triple prehabilitation Intervention
- Where
- 3 sites in China
- Volunteers
- 132 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT01118039
- Testing
- sunitinib malate, immunohistochemistry staining method, laboratory biomarker analysis
- Where
- 4 sites in Spain
- Volunteers
- 41 people
- Sponsor
- Hospital del Mar
Infiltrating Urothelial Carcinoma, Sarcomatoid Variant, Locally Advanced Urothelial Carcinoma
Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma
This phase I trial studies the side effects and best dose of belinostat when given together with durvalumab in treating patients with urothelial cancer that has spread to other places in the body (metastatic) or cannot be removed…
- Conditions
- Infiltrating Urothelial Carcinoma, Sarcomatoid Variant, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
- Trial name
- RESOLVE (NCT05154994)
- Testing
- Belinostat, Durvalumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Utah
HPV-Related Cervical Carcinoma, Physician-Patient Relations
An Observational Study of GP Verbal Reminders Upon Cervical Screening
Cervical cancer screening is offered to all women in the United Kingdom (UK) between the ages of 24.5 and 64 years of age. The majority of screening is performed in primary care and the rate remains stubbornly below 80%, despite…
- Trial name
- VRCS (NCT04970394)
- Testing
- Cervical Screening Reminder
- Where
- United Kingdom
- Volunteers
- 724 people, healthy volunteers welcome
- Sponsor
- Dr. Faizan Awan
Carcinoma, Squamous Cell of Head and Neck
A Post Marketing Surveillance Study of Cetuximab in Patients With Squamous Cell Carcinoma of Head and Neck (SCCHN)
This is a prospective, observational, non-interventional, multicenter, post-marketing surveillance study to mainly collect safety information from subjects with locally advanced and recurrent/metastatic Squamous Cell Carcinoma of…
- Trial name
- NCT01080066
- Testing
- No Intervention
- Where
- Taiwan
- Volunteers
- 215 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Non-small Cell Lung Cancer
Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm
This is an open-label, multi-centre, single-arm study assessing the efficacy and safety of osimertinib as adjuvant treatment in stage IB-IIIB (8th AJCC) NSCLC with uncommon EGFRm after receiving complete surgical resection with…
- Trial name
- NCT05546866
- Testing
- Osimertinib
- Where
- 10 sites in China
- Volunteers
- 51 people
- Sponsor
- AstraZeneca
Esophageal Cancer, Gastroesophageal Junction Cancer
Study of Porcine Fibrin Sealant in Preventing Cervical Anastomotic Leakage for Esophageal or Junctional Carcinoma.
The primary objective is to evaluate the efficacy and assess the role of Porcine Fibrin Sealant (Bioseal®) in preventing cervical anastomotic leakage after esophagectomy in the patients with resectable thoracic esophageal cancer…
- Conditions
- Esophageal Cancer, Gastroesophageal Junction Cancer, Anastomotic Leak
- Trial name
- PLACE020 (NCT03529266)
- Testing
- Porcine Fibrin Sealant (PFS), Surgery
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC)
The primary objective of this study is to assess the efficacy of SIRT as compared with Sorafenib in patients with locally advanced liver cancer in terms of overall survival (OS).
- Trial name
- SIRveNIB (NCT01135056)
- Testing
- SIR-Spheres, Sorafenib tosylate
- Where
- 29 sites in Brunei, Burma and 10 more
- Volunteers
- 360 people
- Sponsor
- Singapore General Hospital
Non-small Cell Lung Cancer
Therapeutic Resistance Prediction of Tyrosine Kinase Inhibitors
The investigators propose a non-invasive prognostic tool for TKIs resistance in patients with stage IV EGFR-mutant non-small cell lung cancer (NSCLC) by computed tomography phenotypic features, which can be conveniently…
- Trial name
- NCT02851329
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Sciences
Carcinoma, Non-Small-Cell Lung
Immune Neoadjuvant Therapy Study of Durvalumab in Early Stage Non-small Cell Lung Cancer
Lung cancer is still the leading cause of cancer related-deaths worldwide, with an overall all-stage 5-year survival of approximately 17%. The primary treatment of early stage (I-IIIA) NSCLC is curative surgery.
- Trial name
- IONESCO (NCT03030131)
- Testing
- Durvalumab
- Where
- 31 sites in France
- Volunteers
- 50 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Fallopian Tube Cancer, Peritoneal Cavity Cancer
Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Fallopian Tube Cancer, Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
- Trial name
- NCT00538031
- Testing
- cyclophosphamide, celecoxib
- Where
- 2 sites in United States
- Volunteers
- 52 people
- Sponsor
- City of Hope Medical Center
Carcinoma, Non-Small-Cell Lung, Melanoma
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
This is a phase I/Ib, open label study. The escalation portion will characterize the safety and tolerability of DKY709 and DKY709 in combination with PDR001 in subjects with NSCLC or melanoma who have received prior…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Melanoma, Nasopharyngeal Carcinoma, Microsatellite Stable Colorectal Cancer
- Trial name
- NCT03891953
- Testing
- DKY709, PDR001
- Where
- 9 sites in United States, Germany and 4 more
- Volunteers
- 98 people
- Sponsor
- Novartis Pharmaceuticals
Urothelial Carcinoma
A Trial of Cabazitaxel for Advanced Transitional Cell Carcinoma (TCC)
In this phase II multicenter study, the investigators aim to evaluate the efficacy and tolerability of a novel taxane-cabazitaxel as single agent second-line chemotherapy for metastatic urothelial carcinoma.
- Trial name
- NCT01600339
- Testing
- CABAZITAXEL
- Where
- 2 sites in Israel
- Volunteers
- 19 people
- Sponsor
- Rambam Health Care Campus
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive…
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma
- Trial name
- NCT06058377
- Testing
- Biospecimen Collection, Cyclophosphamide, Doxorubicin
- Where
- 564 sites in United States, Puerto Rico
- Volunteers
- 3,680 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.